Ajay Duseja , Arka De , Shivaram P. Singh , Kaushal Madan , Padaki N. Rao , Akash Shukla , Gourdas Choudhuri , Sanjiv Saigal , Shalimar , Anil Arora , Anil C. Anand , Ashim Das , Ashish Kumar , Chundamannil E. Eapen , Krishnadas Devadas , Kotacherry T. Shenoy , Manas Panigrahi , Manav Wadhawan , Manish Rathi , Narendra S. Choudhary , Yogesh K. Chawla
{"title":"印度国家肝脏研究协会(INASL)采用代谢功能障碍相关脂肪变性肝病(MASLD)的新命名法:对INASL NAFLD指南文件的影响","authors":"Ajay Duseja , Arka De , Shivaram P. Singh , Kaushal Madan , Padaki N. Rao , Akash Shukla , Gourdas Choudhuri , Sanjiv Saigal , Shalimar , Anil Arora , Anil C. Anand , Ashim Das , Ashish Kumar , Chundamannil E. Eapen , Krishnadas Devadas , Kotacherry T. Shenoy , Manas Panigrahi , Manav Wadhawan , Manish Rathi , Narendra S. Choudhary , Yogesh K. Chawla","doi":"10.1016/j.jceh.2025.102590","DOIUrl":null,"url":null,"abstract":"<div><div>The transition from nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) reflects a paradigm shift in hepatology, emphasising metabolic dysfunction as the central driver in patients with MASLD. This inclusive terminology, endorsed by over 70 international organisations including the Indian National Association for Study of the Liver (INASL), reduces stigma of ‘fatty and alcohol’ and allows the co-existence of other liver disease etiologies along with MASLD. In the present commentary, we discuss the implications of the adoption of new nomenclature of MASLD on the INASL guidance paper on NAFLD, which was published in 2023, before the Delphi consensus on MASLD.</div></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"15 5","pages":"Article 102590"},"PeriodicalIF":3.2000,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Adoption of the New Nomenclature of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) by the Indian National Association for Study of the Liver (INASL): Implications for the INASL Guidance Paper on NAFLD\",\"authors\":\"Ajay Duseja , Arka De , Shivaram P. Singh , Kaushal Madan , Padaki N. Rao , Akash Shukla , Gourdas Choudhuri , Sanjiv Saigal , Shalimar , Anil Arora , Anil C. Anand , Ashim Das , Ashish Kumar , Chundamannil E. Eapen , Krishnadas Devadas , Kotacherry T. Shenoy , Manas Panigrahi , Manav Wadhawan , Manish Rathi , Narendra S. Choudhary , Yogesh K. Chawla\",\"doi\":\"10.1016/j.jceh.2025.102590\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>The transition from nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) reflects a paradigm shift in hepatology, emphasising metabolic dysfunction as the central driver in patients with MASLD. This inclusive terminology, endorsed by over 70 international organisations including the Indian National Association for Study of the Liver (INASL), reduces stigma of ‘fatty and alcohol’ and allows the co-existence of other liver disease etiologies along with MASLD. In the present commentary, we discuss the implications of the adoption of new nomenclature of MASLD on the INASL guidance paper on NAFLD, which was published in 2023, before the Delphi consensus on MASLD.</div></div>\",\"PeriodicalId\":15479,\"journal\":{\"name\":\"Journal of Clinical and Experimental Hepatology\",\"volume\":\"15 5\",\"pages\":\"Article 102590\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-05-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical and Experimental Hepatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0973688325000908\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical and Experimental Hepatology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0973688325000908","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
Adoption of the New Nomenclature of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) by the Indian National Association for Study of the Liver (INASL): Implications for the INASL Guidance Paper on NAFLD
The transition from nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) reflects a paradigm shift in hepatology, emphasising metabolic dysfunction as the central driver in patients with MASLD. This inclusive terminology, endorsed by over 70 international organisations including the Indian National Association for Study of the Liver (INASL), reduces stigma of ‘fatty and alcohol’ and allows the co-existence of other liver disease etiologies along with MASLD. In the present commentary, we discuss the implications of the adoption of new nomenclature of MASLD on the INASL guidance paper on NAFLD, which was published in 2023, before the Delphi consensus on MASLD.